NCT00936065 - Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Moderate to Severe Psoriasis

Interventions

DRUG

Etanercept

Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks

DRUG

Etanercept + Acitretin

Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks

DRUG

Acitretin

Acitretin at a dose of 10mg BID for 24 weeks

Trial Locations (10)

Pfizer Investigational Site, Daejeon